Replimune receives FDA rejection for melanoma treatment RP1
Go back to Replimune receives FDA rejection for melanoma treatment RP1| Rider Explorations, Inc. (NASDAQ: REPL) | Delayed: 8.47 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.47 | 52 Week High | $1.45 | |||
| Open | $8.47 | 52 Week Low | $0.50 | |||
| Day High | $8.47 | P/E | N/A | |||
| Day Low | $8.47 | EPS | $0.00 | |||
| Volume | 5,906 | |||||
